If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Emgality ® (galcanezumab-gnlm) injection100 mg/mL, 120 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
The recommended dose is 120-mg injected subcutaneously once monthly, following an initial 240-mg loading loading dose (administered as 2 consecutive injections of 120 mg each).1
Episodic Cluster Headache Dosing
The recommended dose is 300 mg, 3 consecutive injections of 100 mg each, injected subcutaneously monthly throughout a cluster period.1
Method of Administration
Galcanezumab is for subcutaneous administration.1 A patient may self-inject by following the instructions for use.
Sites for injection include the
back of the upper arm, and
Enclosed Prescribing Information
1. Emgality [package insert]. Indianapolis, IN: Eli Lilly and Company; 2019.
Date of Last Review: April 30, 2019